Press release
Chronic Idiopathic Constipation Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment DelveInsight | ABBVIE, Eisai Co, Anji Pharma, Yuhan, Renexxion Ireland, Forest Lab
"Chronic Idiopathic Constipation Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/chronic-idiopathic-constipation-cic-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Idiopathic Constipation Market.
The Chronic Idiopathic Constipation Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Chronic Idiopathic Constipation Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Chronic Idiopathic Constipation treatment therapies with a considerable amount of success over the years.
*
Chronic Idiopathic Constipation companies working in the treatment market are ABBVIE, Eisai Co., Ltd., Anji Pharma, Yuhan, Renexxion Ireland, Forest Laboratories, Albireo, EA Pharma Co., Ltd., Astellas Pharma Inc, Kissei Pharmaceutical Co., Ltd., Novartis, Theravance Biopharma, SK Life Science, Inc., Movetis, Kissei Pharmaceutical Co., Ltd, Ipsen, and others, are developing therapies for the Chronic Idiopathic Constipation treatment
*
Emerging Chronic Idiopathic Constipation therapies in the different phases of clinical trials are- LINZESS (linaclotide), GOOFICE, ANJ908 (Pradigastat), YH12852, Naronapride, Linaclotide, A3309, AJG555, linaclotide, KWA-0711, Tegaserod, TD-5108, YKP10811, prucalopride, KWA-0711, PEG 4000 (Forlax Registered ), and others are expected to have a significant impact on the Chronic Idiopathic Constipation market in the coming years.
*
In April 2025, Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company focused on advancing transformative therapies for gastrointestinal and rare diseases, announced plans to present real-world evidence at the 2025 Digestive Disease Week Registered (DDW), taking place May 3-6 in San Diego, CA. The presentation will showcase data on the adoption and utilization of newly approved ICD-10 codes in patients with short bowel syndrome (SBS) dependent on parenteral nutrition.
*
In December 2024, NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE American: NRXS), a medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in both children and adults, has announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for its RED (Rectal Expulsion Device). This approval enables NeurAxis to commercially market the device for testing and evaluating patients with chronic constipation caused by pelvic floor dyssynergia, particularly those who are unlikely to see improvement with increased laxative use.
*
In November 2024, Ironwood Pharmaceuticals (Nasdaq: IRWD), a member of the S&P SmallCap 600 Registered , is a leading gastrointestinal (GI) healthcare company dedicated to improving the treatment of GI diseases and setting new standards of care for GI patients. As pioneers in the development of LINZESS Registered (linaclotide), we are proud to lead the U.S. branded prescription market for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).
Chronic Idiopathic Constipation Overview
Chronic Idiopathic Constipation is a condition characterized by long-term, unexplained difficulty in passing stool, often accompanied by infrequent bowel movements, straining, and discomfort. The term "idiopathic" indicates that the cause is unknown, as there are no identifiable underlying medical conditions contributing to the constipation. CIC can significantly affect a person's quality of life and may result in symptoms such as bloating, abdominal pain, and a feeling of incomplete evacuation. It is typically diagnosed when other causes of constipation, such as gastrointestinal disorders or medications, are ruled out. Treatment often involves lifestyle changes, dietary modifications, and medications.
Get a Free Sample PDF Report to know more about Chronic Idiopathic Constipation Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/chronic-idiopathic-constipation-cic-pipeline-insight [https://www.delveinsight.com/report-store/chronic-idiopathic-constipation-cic-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Chronic Idiopathic Constipation Drugs Under Different Phases of Clinical Development Include:
*
A3309: Albireo
*
AJG555: EA Pharma Co., Ltd.
*
linaclotide: Astellas Pharma Inc
*
KWA-0711: Kissei Pharmaceutical Co., Ltd.
*
Tegaserod: Novartis
*
TD-5108: Theravance Biopharma
*
YKP10811: SK Life Science, Inc.
*
prucalopride: Movetis
*
KWA-0711: Kissei Pharmaceutical Co., Ltd
*
PEG 4000 (Forlax Registered ): Ipsen
Chronic Idiopathic Constipation Pipeline Therapeutics Assessment
*
Chronic Idiopathic Constipation Assessment by Product Type
*
Chronic Idiopathic Constipation By Stage and Product Type
*
Chronic Idiopathic Constipation Assessment by Route of Administration
*
Chronic Idiopathic Constipation By Stage and Route of Administration
*
Chronic Idiopathic Constipation Assessment by Molecule Type
*
Chronic Idiopathic Constipation by Stage and Molecule Type
DelveInsight's Chronic Idiopathic Constipation Report covers around products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Chronic Idiopathic Constipation product details are provided in the report. Download the Chronic Idiopathic Constipation pipeline report to learn more about the emerging Chronic Idiopathic Constipation therapies [https://www.delveinsight.com/sample-request/chronic-idiopathic-constipation-cic-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Chronic Idiopathic Constipation Therapeutics Market include:
Key companies developing therapies for Chronic Idiopathic Constipation are - Cosmo Pharmaceuticals NV, Sanofi, Bayer AG, Valeant Pharma, Abbott, AstraZeneca PLC, Pfizer Inc, Takeda Pharma, and others.
Chronic Idiopathic Constipation Pipeline Analysis:
The Chronic Idiopathic Constipation pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Idiopathic Constipation with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Idiopathic Constipation Treatment.
*
Chronic Idiopathic Constipation key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Chronic Idiopathic Constipation Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Idiopathic Constipation market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Chronic Idiopathic Constipation drugs and therapies [https://www.delveinsight.com/sample-request/chronic-idiopathic-constipation-cic-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Chronic Idiopathic Constipation Pipeline Market Drivers
*
Rising Prevalence of Chronic Idiopathic Constipation, Aging Population, Advancements in Drug Development, Increasing Awareness and Diagnosis Rates, Regulatory Approvals and Pipeline Expansion, Growing Investment in Gastrointestinal Research, are some of the important factors that are fueling the Chronic Idiopathic Constipation Market.
Chronic Idiopathic Constipation Pipeline Market Barriers
*
However, High Clinical Trial Failure Rates, Side Effects of Available Treatments, Limited Patient Compliance, High Development Costs, Generic Competition, Regulatory Challenges, and other factors are creating obstacles in the Chronic Idiopathic Constipation Market growth.
Scope of Chronic Idiopathic Constipation Pipeline Drug Insight
*
Coverage: Global
*
Key Chronic Idiopathic Constipation Companies: ABBVIE, Eisai Co., Ltd., Anji Pharma, Yuhan, Renexxion Ireland, Forest Laboratories, Albireo, EA Pharma Co., Ltd., Astellas Pharma Inc, Kissei Pharmaceutical Co., Ltd., Novartis, Theravance Biopharma, SK Life Science, Inc., Movetis, Kissei Pharmaceutical Co., Ltd, Ipsen, and others
*
Key Chronic Idiopathic Constipation Therapies: LINZESS (linaclotide), GOOFICE, ANJ908 (Pradigastat), YH12852, Naronapride, Linaclotide, A3309, AJG555, linaclotide, KWA-0711, Tegaserod, TD-5108, YKP10811, prucalopride, KWA-0711, PEG 4000 (Forlax Registered ), and others
*
bChronic Idiopathic Constipation current marketed and Chronic Idiopathic Constipation emerging therapies
*
Chronic Idiopathic Constipation Market Dynamics: Chronic Idiopathic Constipation market drivers and Chronic Idiopathic Constipation market barriers
Request for Sample PDF Report for Chronic Idiopathic Constipation Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/chronic-idiopathic-constipation-cic-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Chronic Idiopathic Constipation Report Introduction
2. Chronic Idiopathic Constipation Executive Summary
3. Chronic Idiopathic Constipation Overview
4. Chronic Idiopathic Constipation- Analytical Perspective In-depth Commercial Assessment
5. Chronic Idiopathic Constipation Pipeline Therapeutics
6. Chronic Idiopathic Constipation Late Stage Products (Phase II/III)
7. Chronic Idiopathic Constipation Mid Stage Products (Phase II)
8. Chronic Idiopathic Constipation Early Stage Products (Phase I)
9. Chronic Idiopathic Constipation Preclinical Stage Products
10. Chronic Idiopathic Constipation Therapeutics Assessment
11. Chronic Idiopathic Constipation Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Chronic Idiopathic Constipation Key Companies
14. Chronic Idiopathic Constipation Key Products
15. Chronic Idiopathic Constipation Unmet Needs
16 . Chronic Idiopathic Constipation Market Drivers and Barriers
17. Chronic Idiopathic Constipation Future Perspectives and Conclusion
18. Chronic Idiopathic Constipation Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-idiopathic-constipation-pipeline-2025-moa-roa-fdaapproved-drugs-and-clinical-trial-progress-assessment-delveinsight-abbvie-eisai-co-anji-pharma-yuhan-renexxion-ireland-forest-lab]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Idiopathic Constipation Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment DelveInsight | ABBVIE, Eisai Co, Anji Pharma, Yuhan, Renexxion Ireland, Forest Lab here
News-ID: 4150771 • Views: …
More Releases from ABNewswire
Total Joy Homecare Responds to Surging Demand for Senior Health Care Services in …
Total Joy Homecare expands services to meet growing Houston demand for in-home senior care, offering non-medical support that helps families maintain independence and dignity at home.
Houston's rapidly aging demographic has prompted local care provider Total Joy Homecare to expand its comprehensive support services, addressing the critical need for quality senior health care services [https://maps.app.goo.gl/hUcW1N7qWy5EdHJs5] throughout the Greater Houston area. The company's response comes as families increasingly seek reliable alternatives to…
Texas Company Introduces On-Site Carrier Repair Services to Reduce Fleet Downtim …
Texas Reefer Solutions introduces mobile carrier repair services in Dallas, revolutionizing how transportation fleets handle refrigeration breakdowns by providing on-site professional repairs, eliminating route deviations, and reducing cargo-threatening delays.
The transportation industry faces a significant challenge when refrigerated trucks require repairs, often forcing drivers to deviate from critical routes and schedules. Texas Reefer Solutions has emerged as a game-changing solution, introducing mobile carrier repair services [https://maps.app.goo.gl/P6nfg5WF7sckR7aZ8] that bring professional technicians directly…
Family Therapy in Birmingham: How the Right Therapist Can Transform Relationship …
Family therapy in Birmingham helps families improve communication, resolve conflict, and build stronger bonds. With the support of a qualified therapist near you, therapy creates a safe space to share, heal, and reconnect. Whether you're searching for therapy near me or counselling for your family, Phinity Therapy offers guidance for lasting change.
Families are the foundation of our lives. They provide love, support, and connection, but they can also be the…
Multiple Sclerosis Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Tri …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Multiple Sclerosis pipeline constitutes 75+ key companies continuously working towards developing 80+ Multiple Sclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Multiple Sclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
More Releases for Chronic
Chronic Pain Treatment Market - Relieving Chronic Pain: Discover the Latest Inno …
Newark, New Castle, USA: The "Chronic Pain Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Chronic Pain Treatment Market: https://www.growthplusreports.com/report/chronic-pain-treatment-market/8030
This latest report researches the industry structure,…
Refractory Chronic Cough Therapeutics Market - Silencing the Cough: Innovative T …
Newark, New Castle, USA: The "Refractory Chronic Cough Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Refractory Chronic Cough Therapeutics Market: https://www.growthplusreports.com/report/refractory-chronic-cough-therapeutics-market/7991
This latest report researches the…
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Chronic Hepatitis Therapeutics Market - Empowering Liver Health, Defying Chronic …
Newark, New Castle, USA - new report, titled Chronic Hepatitis Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Hepatitis Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Hepatitis Therapeutics market. The report offers an overview of…
Chronic Phase Chronic Myeloid Leukemia Market to Witness Growth by 2032, Estimat …
DelveInsight's "Chronic Phase Chronic Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chronic Phase Chronic Myeloid Leukemia , historical and forecasted epidemiology as well as the Chronic Phase Chronic Myeloid Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Chronic Phase Chronic Myeloid Leukemia market report provides current treatment practices, emerging drugs, the market share…
Boot chronic pain
For immediate release
Due to our rushed lives and stressful environment, many people are suffering from chronic pain and fatigue.
We feel permanently tired and are barely able to get through our normal day. One is able to change this status when following the guidelines the book "Tired of being Tired to the point of being Gatvol (Fed Up). Some people will need a team of medical practitioners to help them…
